Cyclophosphamide Administration Guidelines

Dosing Regimens

The American College of Rheumatology recommends cyclophosphamide administration either as oral daily therapy (1-3 mg/kg/day) or as intravenous pulse therapy (15 mg/kg every 2-4 weeks) with mesna protection, accompanied by adequate hydration and appropriate monitoring for toxicity 1, 2
Typical oral dosing is 1-3 mg/kg/day (maximum 200 mg/day) for adults, with dose adjustments based on white blood cell counts 1, 2
For children, oral dosing is typically 1.5-3 mg/kg/day 3
Intravenous pulse dosing is 15 mg/kg (maximum 1500 mg) given initially every 2 weeks, then reducing to every 3 weeks, with alternative fixed-dose regimens including 500-1000 mg monthly 4, 5, 6

The European League Against Rheumatism recommends that all patients receiving pulse cyclophosphamide should receive mesna (2-mercaptoethanesulfonate sodium) to prevent hemorrhagic cystitis, which occurs in up to 6% of patients 1, 2, 4, 6
Mesna binds to acrolein (toxic metabolite) and reduces urinary tract toxicity, and may also benefit patients on continuous oral cyclophosphamide 1, 2

The American College of Rheumatology strongly recommends Pneumocystis jiroveci prophylaxis for all patients on cyclophosphamide, with a preferred regimen of trimethoprim/sulfamethoxazole (800/160 mg on alternate days or 400/80 mg daily) 1, 2
Alternative prophylaxis should be considered if trimethoprim/sulfamethoxazole is contraindicated 1

Regular liver function tests should be monitored, particularly in patients with pre-existing liver disease 3
Dose adjustments or discontinuation may be necessary in the event of acute leukopenia or gradual decline in counts 1

For remission induction in generalized ANCA-associated vasculitis, cyclophosphamide with glucocorticoids (prednisolone 1 mg/kg/day, max 60 mg/day) is recommended, with a duration typically 3-6 months for remission induction 1, 2, 7
In anti-GBM disease, oral cyclophosphamide at 2-3 mg/kg for 2-3 months, with dose adjustment for reduced GFR or older age, is recommended, used in combination with plasma exchange and glucocorticoids 7
For pemphigus vulgaris, intravenous cyclophosphamide (15 mg/kg monthly) can be combined with conventional oral corticosteroids, best reserved for severe or recalcitrant cases due to long-term toxicity concerns 4

Cyclophosphamide can cause amenorrhea (20-85% of menstruating women) and azoospermia in men, with a long-term risk of secondary malignancies 3, 4, 6
Mesna administration is crucial for preventing hemorrhagic cystitis, which occurs in up to 6% of patients 4, 6

Amenorrhea occurs in 20-85% of menstruating women, with risk increasing with age and cumulative dose, according to the American Journal of Kidney Diseases 8
Fertility preservation should be considered before initiating therapy, especially in younger patients, as recommended by the American Journal of Kidney Diseases 8
The Euro-Lupus cyclophosphamide regimen (total dose: 3 grams) carries a lower risk of infertility than oral or NIH regimens, as reported by the American Journal of Kidney Diseases 8

Intravenous pulse therapy generally results in lower cumulative doses than daily oral therapy, as found in a study published in Kidney International 9
The CYCLOPS study showed that while IV cyclophosphamide caused less leukopenia, it was associated with higher relapse rates compared to oral administration, according to Kidney International 9

In patients with ANCA-associated vasculitis who remain on dialysis without extrarenal manifestations, immunosuppression should be discontinued after 3-6 months to reduce infection risk, as recommended by the American Journal of Kidney Diseases 10
Patients with lupus nephritis receiving cyclophosphamide should be counseled about infertility risks, with shared decision-making guiding therapy and interventions, according to the American Journal of Kidney Diseases 8